Rhenman & Partners Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Rhenman & Partners Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-136,000	Closed	-$16.1M	–	96
2022 Q1	$16.1M	Sell	136,000 -14,000	-9%	-$1.75M	1.59%	25
2021 Q4	$20.7M	Buy	150,000 +15,000	+11%	+$1.91M	1.38%	26
2021 Q3	$18.8M	Sell	135,000 -65,419	-33%	-$8.17M	1.32%	30
2021 Q2	$19.5M	Hold	200,419	–	–	1.32%	33
2021 Q1	$13.7M	Sell	200,419 -34,581	-15%	-$2.8M	0.96%	42
2020 Q4	$20.1M	Sell	235,000 -75,000	-24%	-$6.36M	1.64%	24
2020 Q3	$20.2M	Buy	310,000 +100,000	+48%	+$6.55M	1.79%	20
2020 Q2	$15.4M	Buy	210,000 +70,000	+50%	+$3.73M	1.66%	22
2020 Q1	$4.76M	Buy	140,000 +15,000	+12%	+$686K	0.67%	54
2019 Q4	$6.8M	Buy	+125,000	New	+$6.19M	0.75%	56

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rhenman & Partners Asset Management's BHVN Position: Q2 2022 in Review

Rhenman & Partners Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 136,000 shares — an estimated $16.1M sold.

Rhenman & Partners Asset Management first reported a position in BHVN in Q4 2019 and held it in 10 quarters. The position peaked at $20.7M in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Rhenman & Partners Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Rhenman & Partners Asset Management sold 136,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $16.1M.
Rhenman & Partners Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 10 quarters.
Rhenman & Partners Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $20.7M in Q4 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.